Announcement
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_37.png%3Fitok%3Dwv-ux4QQ)
Read recent updates from the Advanced & Cell Therapies team led by Professor Fiona Thistlethwaite and about the recent appointment of Dr Emma Searle to the Haematology team within the Manchester ECMC
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_36.png%3Fitok%3DEqR5cjZX)
Read about the ACCEPT (a phase Ib/II) and ProCAID (placebo controlled randomised phase II) trials taking place at Southampton ECMC
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_35.png%3Fitok%3DzPRBV2pu)
Biospecific antibodies are showing promising activity in early phase trials in relapsed/refractory Non-Hodgkin lymphoma (NHL), including patients that have received prior CAR-T therapies.
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_34.png%3Fitok%3DaS0MB5eG)
Two trials from the Trials Acceleration Programme (TAP) will be opening across the UK - VICTOR and PROMise
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_33.png%3Fitok%3D-3bCTHdQ)
Researchers in the University of Sheffield Department of Oncology and Metabolism have formed a new university spinout company (Modulus Oncology) with experienced drug development entrepreneurs Dr Clare Wareing and Dr Alan Wise from Edinburgh-based bioincubator company Cumulus Oncology.
![ECMC Logo](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_32.png%3Fitok%3DG-HvWQ1w)
Researchers from the University of Cambridge and Cold Spring Harbour Laboratory (CSHL) have completed an early phase clinical trial of a drug called plerixafor showing that it induces an integrated immune response in the tumours of patients with cancer types that do not usually respond to immunotherapy.
![ECMC Logo](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_31.png%3Fitok%3DvtBLW00I)
The teams from ECMC North delivered successfully their first on-line educational event on October 19th 2020. We have now moved to developing the content for the ECMC COVID-19 Community Hub, a curated on-line platform to build on the learnings from the workshops held in October.
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_28.png%3Fitok%3DeX_MZvHB)
The teams from ECMC North successfullly delivered their first online educational event on 19 October 2020. We have now moved to developing the content for the ECMC COVID-19 Community Hub, a curated online platform to build on the learnings from the workshops held in October.
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_27.png%3Fitok%3Dvw0mMkFp)
Wondering what other centres do to overcome the challenges of COVID-19 for early phase trials? Interested in contributing to sharing best practice? Don’t know who to ask about COVID-19 implications when planning future trials? Then join ECMC North in the educational event to help develop a framework for delivery during the pandemic.
![](://stage.ecmcnetwork.org.uk/%3A//stage.ecmcnetwork.org.uk/sites/default/files/styles/listing_preview/public/ECMCLogo_Website_News_26.png%3Fitok%3D9su3NrFQ)
Below are two examples of work being done in Manchester to support the COVID effort.